kfcyahoo...
you state about LEO leadership of IPIX:
"The reason IPIX is a pink sheet penny stock is because its CEO is a lying, incompetent, grasping clown."
One question...EXACTLY WHO IS (ARE) THE "LYING, INCOMPETENT, GRASPING CLOWN(S)"?
Leo...achieved much in 2020 with little financial resources...and backing...and is doing the same in 2021...
the following below demonstrate his accomplishments in furthering BRILACIDIN as a THERAPY to combat COVID-19.
NOW ...add to the list.... "FAST TRACK DESIGNATION" ...recognition by the FDA of reasonable potential of HUGE VALUE!
...detractors of Leo have only identified possibly two other biotech who received for a therapeutic candidate...maybe...who have received FTD for a Covid-19 Therapeutic candidate...
My response to your criticism: (if that is your definition of a CLOWN)
..."BRING ON THE CLOWNS!"
________________________________________________________________________
Accomplishments in 2020 and 2021 ... SO FAR:
-2/18 Initial announcement of Brilacidin for Covid 19
-2/24 Material transfer agreements to virology labs
-2/28 Brilacidin sent to Regional Biodefense Labs {RBL)for study
-3/2 Brilacidin PDF outlines scientific rationale for use against Covid19
-3/9 Brilacidin studies planned at RBL
-3/12 Testing to begin 3/16
-4/1 Brilacidin effective against Covid19 in Vero monkey cells
-4/6 Early discussions of human trials
-4/20 Screening of 11,552 compounds shows Brilacidin a leading drug against Covid19 by inhibiting the M-protease
-4/27 Initial research confirms anti Covid properties more research planned
-5/5 PHRI studies announced
-5/19 Brilacidin reduces Covid 75% in preincubtion Vero cell study
-5/26 Brilacidin reduces Covid in human renal cell line; blocks viral cell entry
-6/11 Brilacidin study to include MERS and SARS pan corona virus testing; Grant application application made
-6/17 Brilacidin inhibits Covid 97% in infected Human respiratory cells
-7/7 Brilacidin active against Covid 19 before during and after Covid infects cells
-7/13 Human clinical trial planning/manufacture of Brilacidin announced
-7/20 Brilacidin at low dosage is effective against Covid19; lower than ABSSI dose
-8/4 Brilacidin shown effective against entire Covid life cycle
-8/24 Brilacidin Selectivity index among highest reported
-8/26 Dr Degrado announced as science advisor
-9/15 Brilacidin synergistic with remdesivir;reduces viral load almost 100%
-10/2 Pre IND meeting; Brilacidin human clinical trials
-10/30 RBL preprint article released; Selectivity index 426 one of highest achieved
-11/2 FDA pre IND response received;CRO secured
-11/16 Overseas CTA submitted;Brilacidin viral resistance unlikely
-11/30 New research for Brilacidin as a pancoronavirus treatment
FDA application submitted
-12/21 Brilacidin for phase 2 Covid study approved
- 1/2021....NOW ... FAST TRACT DESIGNATION!!!
News 
Market Data 
Discover 
